EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecularly diagnosed glioblastoma: clinical presentation and outcomes

Harold F Hounchonou iD, Manolis Polemikos, Ariyan Pirayesh, Genis Bajgora, Shadi Al-Afif, Christian Hartmann, Joachim K Krauss

Journal of Neuro-Oncology · 2026

DOI: 10.1007/s11060-026-05752-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Harold F Hounchonou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany. hounchonou.harold@mh-hannover.de. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2021 WHO classification permits diagnosis of glioblastoma in IDH-wildtype diffuse astrocytic tumors with TERT promoter mutation, EGFR amplification, or chromosome 7 gain/10 loss, even without necrosis or microvascular proliferation. The clinical behavior of these molecularly defined glioblastomas (molGBM) remains uncertain.

Methods

We retrospectively analyzed patients with molGBM treated at Hannover Medical School between 2017 and 2024. A contemporaneous histologically defined glioblastoma cohort (hisGBM) served as a control group in an approximately 1:3 ratio. MolGBM were stratified by histological grade and additionally compared with IDH-mutant astrocytomas of corresponding grade. Survival was assessed using Kaplan-Meier analysis, Cox regression, and propensity score matching.

Results

Thirty-four patients with molGBM and 103 with hisGBM were included. Compared with hisGBM, molGBM patients were younger ( p < 0.001), had higher Karnofsky Performance Status ( p < 0.001), and more often presented with seizures ( p = 0.006), whereas focal neurological deficits were more frequent in hisGBM. MolGBM showed less contrast enhancement ( p < 0.001) and lower Ki-67 indices ( p < 0.001). Median overall survival was longer in molGBM (539 vs. 374 days; p = 0.032), but tumor group was not independently associated with survival after adjustment for age and KPS (HR 1.21, 95% CI 0.77–1.90; p = 0.411). In the matched cohort, overall survival did not differ significantly (517 vs. 468 days; p = 0.670). MolGBM had inferior survival to grade-corresponding IDH-mutant astrocytomas ( p < 0.001).

Conclusions

MolGBM shows a distinct clinical-radiological phenotype, while its apparent survival advantage over hisGBM is influenced by baseline clinical differences. Clinical trial number Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansMaleRetrospective StudiesFemaleMiddle AgedMutationIsocitrate DehydrogenaseAgedAdultPrognosisFollow-Up StudiesSurvival RateBiomarkers, TumorTelomerase

Stichwörter der Autor:innen

GlioblastomaHigh grade gliomaIDH-wildtype gliomaMolecular glioblastomaNon-enhancing glioblastoma

Substanzen

Isocitrate DehydrogenaseBiomarkers, TumorTelomerase

Autor:innen und Institutionen

  • Department of Neurosurgery, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany. hounchonou.harold@mh-hannover.de.
  • Department of Neurosurgery, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany.
  • Department of Neuropathology, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany.

ORCID-Profile: Harold F Hounchonou

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Hounchonou, H. F., Polemikos, M., Pirayesh, A., Bajgora, G., Al-Afif, S., Hartmann, C., & Krauss, J. K. (2026). Molecularly diagnosed glioblastoma: clinical presentation and outcomes. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05752-8

Vancouver

Hounchonou HF, Polemikos M, Pirayesh A, Bajgora G, Al-Afif S, Hartmann C, et al. Molecularly diagnosed glioblastoma: clinical presentation and outcomes. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05752-8

BibTeX
@article{Hounchonou2026,
  author = {Hounchonou, Harold F and Polemikos, Manolis and Pirayesh, Ariyan and Bajgora, Genis and Al-Afif, Shadi and Hartmann, Christian and Krauss, Joachim K},
  title = {Molecularly diagnosed glioblastoma: clinical presentation and outcomes},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  doi = {10.1007/s11060-026-05752-8}
}
Kostenlos starten →